Search

Sonodynamic therapy (SDT), a tumor treatment modality with high tissue penetration and low side effects, is able to selectively kill tumor cells by producing cytotoxic reactive oxygen species (ROS) with ultrasound‐triggered sonosensitizers. N‐type inorganic semiconductor TiO2 has low ROS quantum yields under ultrasound irradiation and inadequate anti‐tumor activity. Herein, by using atomic layer deposition (ALD) to create a heterojunction between porous TiO2 and CoOx, the sonodynamic therapy efficiency of TiO2 can be improved. Compared to conventional techniques, the high controllability of ALD allows for the delicate loading of CoOx nanoparticles into TiO2 pores, resulting in the precise tuning of the interfaces and energy band structures and ultimately optimal SDT properties. In addition, CoOx exhibits a cascade of H2O2→O2→·O2− in response to the tumor microenvironment, which not only mitigates hypoxia during the SDT process, but also contributes to the effect of chemodynamic therapy (CDT). Correspondingly, the synergistic CDT/SDT treatment is successful in inhibiting tumor growth. Thus, ALD provides new avenues for catalytic tumor therapy and other pharmaceutical applications. [ABSTRACT FROM AUTHOR]

A series of novel monodisperse, well-defined molecules with a pyridine core and carbazole arms were synthesized by simple procedures with Iodo-reaction and . Their structures were confirmed by IR, 1H NMR, 13C NMR, and elementary analysis. Moreover, the fluorescence spectra showed that these compounds exhibited strong fluorescence with the maximum wavelengths ranging from 373 to 385 nm. [ABSTRACT FROM AUTHOR]

Hepatitis B virus (HBV) infection is a dynamic process during which molecular variants are selected continuously to adapt to changes. In addition to drug resistant mutations, sequential antiviral therapy may also lead to the selection of deleted mutants. To investigate this process, the following samples were collected from a patient who failed lamivudine therapy and then was switched to adefovir dipivoxil. HBV DNA was sequenced at two separate regions; a 1 kb region of reverse transcriptase (RT) and a 1.5 kb region encompassing the C gene and part of the preS gene. Sequence analysis of the RT region showed that the prevailing lamivudine resistant mutations were reduced after switching to adefovir dipivoxil, and ultimately the mutations were undetectable. Quasispecies distribution and deletion patterns in the C and preS regions were also different between the two antiviral therapies. In lamivudine-treated samples, wild-type strains (57.7%) were dominant and deletions in the preS region were observed. However, in the subsequent therapy involving adefovir dipivoxil, a virus population harboring 81 and 96 bp deletions (86%) in the C gene prevailed. Both major deletions encompassed T- and B-cell epitopes. Meanwhile, the frequencies of the preS deletions decreased significantly, except for the 129 bp deletion. Notably, the presence of 81, 96, and 129 bp deletions was always accompanied with some nucleotide substitutions. In conclusion, the prevalence of deletions at the C gene epitopes accompanied with the gradual disappearance of lamivudine resistance mutations may contribute to the survival of HBV under sequential antiviral therapy. J. Med. Virol. 81:1551-1559, 2009. © 2009 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]